Diagnosis

Urolithiasis

  • Nephrolithiasis: Renal stones are formed within the kidneys

  • Urolithiasis: The presence of calculi in the urinary tract (kidney, bladder or urethra).

Also known as: Kidney stones, Nephrolithiasis, Renal calculi

Etiology

Cause [cyu]

Patholphysiology [cyu]

  1. Crystals supersaturate the urine due to high concentration --> crystallize forming the renal calculi

  2. These crystals aggregate together and continue to enlarge with the potential to migrate into the ureter and become symptomatic

  3. Obstruction --> hydronephrosis --> severe colicky pain

  4. Three most common location for a stone to obstruct:

    • Ureteropelvic junction (UPJ)

    • Ureter crosses over the iliac vessels

    • Ureterovesical junction (UVJ)

Risk factors [cyu][3as]

Complications [3as]

Epidemiology

Incidence per 100.000 [ow9][d47][cym][p1e][she]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Diarrhea, Fever, Hematuria, Kehr's sign, Nausea, Vomiting

Clinical findings

Elevated CRP, Hydronephrosis, Hydroureter, Leukocytosis, Perinephric stranding, Ureteral obstruction, Urinary retention

Anamneses

None listed.

Localized findings

Pain
Radiates
Right flankLeft flankGenitalInguinalScrotumVulva
Onset
Hyperacute (seconds)Acute (minutes)
Pattern
ConstantIntermittent
Quality
Colicky
Severity
Moderate (4-7)Severe (8-10)
Swelling
Radiates
Abdomen
Onset
Subacute (hours)
Pattern
ConstantIncreasing

Approach

Treatment

  1. Prophylaxis: [cyu][3as]

    • Oral hydration that produces approximately 2.5 L of urine per day

    • Consumption of citrate and calcium (binds oxalate in the GI tract)

  2. Non-operative management: 86% will pass spontaneously [cyu]

    ≤ 2 mm: 8 days for mean passage and passage rate of 87%

    3 mm stones, 12 days for mean passage and passage rate of 76%

    4-6 mm, 22 days for mean passage and passage rate of 60%

    7 mm stone with a passage rate of 48%

    8-9 mm stone with a passage rate of 25%

    • Expectant management

    • Analgesic: NSAIDs, Opioids reserved for refractory pain

    • Nausea and vomiting: Anti-emetic medications such as ondansetron, metoclopramide, promethazine

    • Medical expulsive therapy facilitate passage of larger (5-10 mm) stones: alpha-blockers such as doxazosin and tamsulosin

  3. Surgical intervention to removal the stone: obstruction, oligouria, acute renal failure, infection, solitary kidney

    • JJ-stent for rapid renal decompression

    • Extracorporeal shockwave lithotripsy (ESWL): proximal stones

    • Flexible ureteroscopy (URS): lower pole stones between 1.5 and 2 cm

    • Percutaneous nephrolithotomy (PCNL): if failed ESWL/URS or >20mm proximal stones

Differential diagnoses

Abdominal abscess, Abortion, Acute mesenteric ischemia, Acute pancreatitis, Aortic dissection, Appendicitis, Cholecystitis, Constipation, Diverticulitis, Dysmenorrhea, Gastrointestinal obstruction, Glomerulonephritis, Ovarian torsion, Pelvic inflammatory disease, Pyelonephritis, Pyonephrosis, Ruptured aortic aneurysm, Ruptured ectopic pregnancy, Urinary tract infection, Xanthogranulomatous pyelonephritis


References

[1] Thakore P, Liang TH. Urolithiasis. Updated 2023 Jun 5: https://www.ncbi.nlm.nih.gov/books/NBK559101/

[2] Leslie SW, Sajjad H, Murphy PB. Renal Calculi, Nephrolithiasis. Updated 2024 Apr 20: https://www.ncbi.nlm.nih.gov/books/NBK442014/

[3] Zhang L, Zhang X, Pu Y, Zhang Y, Fan J. Global, Regional, and National Burden of Urolithiasis from 1990 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Clin Epidemiol. 2022 Aug 15;14:971-983. Supplementary Figure 3A

[4] Qian X, Wan J, Xu J, Liu C, Zhong M, Zhang J, Zhang Y, Wang S. Epidemiological Trends of Urolithiasis at the Global, Regional, and National Levels: A Population-Based Study. Int J Clin Pract. 2022 Mar 30;2022:6807203.

[5] GBD 2021 Urolithiasis Collaborators. The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000-2021: a systematic analysis for the Global Burden of Disease Study 2021. EClinicalMedicine. 2024 Nov 21;78:102924.

[6] Li S, Huang X, Liu J, Yue S, Hou X, Hu L, Wu J. Trends in the Incidence and DALYs of Urolithiasis From 1990 to 2019: Results From the Global Burden of Disease Study 2019. Front Public Health. 2022 Mar 4;10:825541.

[7] Huang H, Li M, Fan H, Bai R. Temporal Trend of Urolithiasis Incidence in China: An Age–Period–Cohort Analysis. Int J Gen Med. 2021;14:2533-2539

[8] http://emedicine.medscape.com/article/437096 (2014-01-02); [Medscape]

Scroll to top